Sierra’s Cutting-edge Clinical Research Information System (CRISV8) Is Configured & Supported for Trials of any Scale at the Largest Institutions
-- System to debut at 41st Annual DIA Mtg, Washington DC, June 26-29, Booth 1457
EMERYVILLE CA USA -- JUNE 16 2005 -- Sierra Scientific Software, a leading provider of integrated clinical research software solutions, announced the debut today of its leading-edge eClinical Trial Solution, which is capable of supporting all of the clinical research at the largest institutions.
IMPLEMENTATION OF CRIS PROVIDES INSTITUTIONS:
- Intuitive, easy-to-use Web-enabled interface
- Secure portal for EDC, & all site access & communications
- "Project View" to aggregate information across multiple studies
- Configurable workflow management, with active alerts to identify events such as document expiration dates, safety reporting deadlines & site communications
- Enhanced Safety Tracking, including support for MedDRA coding, E2B electronic submission & ever-changing regulatory standards
- Integrates with other enterprise applications, including: Project Management, Document Management, MRP, Finance, plus other Clinical applications
- Support for key data interchange standards, including CDISC LABS & ODM
SUPPORTS UNLIMITED NUMBER OF TRIALS, ANY SIZE:
David Thomas, Sierra's CEO, states, "Culminating 10 years of development, 8 versions and rigorous use by industry, with CRIS v8 we have created a complete information management system for eClinical Trials." (The specification sheet is below:)
http://sacserv.com/links.jsp?linkid=20909&subid=686369&custid=76&campid=142247&type=0
"CRIS supports an unlimited number of trials of any size, and with the customer support provided by our partner, SAIC, 24/7 global help-desk and robust hosting services make it easy to implement. With CRIS, the institution can connect all participants in the trial process, from investigators, clinical data centers, IRBs and sponsors. With CRIS, every investigator has access to state-of-the-art technology, capital and training costs are reduced and all stakeholders are integrated into the trial process. We are confident that CRIS provides institutions with an outstanding value proposition and will be pleased to show you why," says Thomas.
CRISv8 is the result of a joint development program through the strategic alliance between Sierra Scientific Software, Inc. (Sierra) and Science Applications International Corp (SAIC). CRIS is developed within SAIC's stringent development processes, procedures, and supported by SAIC's world-class hosting, 24/7 help desk and implementation service capabilities; as used by the largest entities, such as Bristol Myers Squibb and the National Cancer Institute.
The SAIC/Sierra Alliance provides comprehensive service and support functions to implement CRIS in-house, as a hosted service, or accessed on an ASP basis. Services are available from SAIC's ISO 9001:2000-certified North American Integrated Services Management Center (NAISMC). These services include customization, integration, validation, data migration and user training. A global 24/7 Help Desk, in languages as required, is also available. For additional information regarding SAIC's capabilities, access the brochure, Pharmaceutical/Biotechnology IT Challenges:
http://sacserv.com/links.jsp?linkid=20910&subid=686369&custid=76&campid=142247&type=0
"Using CRISv8 means institutions and their investigator's have at their fingertips the tools to execute world-class clinical research," Thomas concludes.
DIA EXHIBITION:
Come see Sierra, SAIC and CRIS v8 at the 41st Annual DIA meeting in Washington DC, on June 26-29 2005, at Booth 1457.
Visit the websites below to learn more about the companies' combined capabilities:
http://sacserv.com/links.jsp?linkid=20911&subid=686369&custid=76&campid=142247&type=0
http://sacserv.com/links.jsp?linkid=20912&subid=686369&custid=76&campid=142247&type=0
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
